Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.
Ziihera received accelerated approval based on results including a 52% objective re...
Nov. 21, 2024
Industry’s first wide bore, high-performance helium-free [1] 1.5T MR features AI assistance at every step in the MRI workflow, with seamless integration of cloud-based AI image rea...
